 |
63 Diseases |  |
0 Trials |
|
0 Trials |  |
32 News |  |
- | Telcyta (canfosfamide) / MabVax
Journal: Human GST P1-1 Redesigned for Enhanced Catalytic Activity with the Anticancer Prodrug Telcyta and Improved Thermostability. (Pubmed Central) - Feb 24, 2024
The mutation Q85R was identified as an important contributor to the regained thermostability. These results represent a first step towards a functional ADEPT application for Telcyta.
- | Telcyta (canfosfamide) / MabVax
Journal: Characterization of Dog Glutathione Transferase P1-1, an Enzyme Relevant to Veterinary Medicine. (Pubmed Central) - May 14, 2021
Among established GST inhibitors, Cibacron Blue showed positive cooperativity with an IC value of 43 nM. Dog GST P1-1 catalyzes activation of the prodrug Telcyta, but the activity is significantly lower than that of the human homolog.
- | Telcyta (canfosfamide) / MabVax
My memory says don’t believe in Telcyta. (Twitter) - Oct 20, 2019
- ||||||| Telcyta (canfosfamide) / MabVax
Trial completion, Combination therapy: TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer (clinicaltrials.gov) - Feb 22, 2014
P3, N=244, Completed, Sponsor: Telik
Dog GST P1-1 catalyzes activation of the prodrug Telcyta, but the activity is significantly lower than that of the human homolog. Active, not recruiting --> Completed
- |||| Telcyta (canfosfamide) / MabVax
Trial completion, Metastases: Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov) - Feb 22, 2014
P1/2, N=100, Completed, Sponsor: Telik
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Telcyta (canfosfamide) / MabVax
Trial completion, Metastases: Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) - Feb 22, 2014
P3, N=520, Completed, Sponsor: Telik
Active, not recruiting --> Completed No longer recruiting --> Completed
- | Telcyta (canfosfamide) / MabVax
Trial completion, Combination therapy, Metastases: TLK286 (Telcyta) in Combination With Cisplatin for Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Feb 22, 2014
P1/2, N=50, Completed, Sponsor: Telik
No longer recruiting --> Completed No longer recruiting --> Completed
- ||||||| Telcyta (canfosfamide) / MabVax
Trial completion: TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer (clinicaltrials.gov) - Feb 22, 2014
P3, N=440, Completed, Sponsor: Telik
No longer recruiting --> Completed No longer recruiting --> Completed
- | Telcyta (canfosfamide) / MabVax
Trial completion, Combination therapy: TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer (clinicaltrials.gov) - Feb 22, 2014
P1/2, N=28, Completed, Sponsor: Telik
No longer recruiting --> Completed No longer recruiting --> Completed
- | Telcyta (canfosfamide) / MabVax
Trial completion, Combination therapy: TLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian Cancer (clinicaltrials.gov) - Feb 22, 2014
P1/2, N=28, Completed, Sponsor: Telik
No longer recruiting --> Completed No longer recruiting --> Completed
- | Telcyta (canfosfamide) / MabVax
Trial completion, Combination therapy: Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer (clinicaltrials.gov) - Feb 22, 2014
P1/2, N=28, Completed, Sponsor: Telik
No longer recruiting --> Completed No longer recruiting --> Completed
- | Telcyta (canfosfamide) / MabVax
Trial completion, Metastases: Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov) - Feb 22, 2014
P2, N=40, Completed, Sponsor: Telik
No longer recruiting --> Completed No longer recruiting --> Completed
- | Telcyta (canfosfamide) / MabVax
Trial completion: Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer (clinicaltrials.gov) - Feb 22, 2014
P2, N=40, Completed, Sponsor: Telik
No longer recruiting --> Completed No longer recruiting --> Completed
- | Telcyta (canfosfamide) / MabVax
Trial completion, Metastases: TLK286 in Treating Patients With Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov) - Feb 22, 2014
P2, N=0, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
No longer recruiting --> Completed Active, not recruiting --> Completed
- |||| Telcyta (canfosfamide) / MabVax
Trial completion, Metastases: Phase 2 Study of TLK286 in Metastatic Breast Cancer (clinicaltrials.gov) - Feb 22, 2014
P2, N=60, Completed, Sponsor: Telik
Active, not recruiting --> Completed No longer recruiting --> Completed
- | Telcyta (canfosfamide) / MabVax
Trial completion: TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
No longer recruiting --> Completed Active, not recruiting --> Completed
- | Telcyta (canfosfamide) / MabVax
Trial termination, Combination therapy: ASSIST-5: Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer (clinicaltrials.gov) - Nov 25, 2013
P3, N=244, Terminated, Sponsor: Telik
Active, not recruiting --> Completed Completed --> Terminated; Business reasons
- | Telcyta (canfosfamide) / MabVax
Enrollment change: Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma (clinicaltrials.gov) - Mar 12, 2013
P2, N=14, Completed, Sponsor: Telik
Completed --> Terminated; Business reasons N=45 --> 14
- | Telcyta (canfosfamide) / MabVax
Trial completion: Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma (clinicaltrials.gov) - Mar 12, 2013
P2, N=14, Completed, Sponsor: Telik
N=45 --> 14 Active, not recruiting --> Completed